Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03095781 | Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 47 | Emory UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT00629759 | A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma | completed | Phase 1 | 14 | Jennerex BiotherapeuticsINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT03017807 | Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 18 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 12, 2026 | clinicaltrials |
| NCT03767582 | Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas. | completed | Phase 1 / Phase 2 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03851237 | CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy | completed | Phase 1 | 69 | Washington University School of MedicineOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03552718 | QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. | completed | Phase 1 | 5 | NantBioScience, Inc.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT05111353 | Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery | completed | Phase 1 | 33 | Washington University School of MedicineOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04358185 | Itacitinib in Advanced Hepatocellular Carcinoma(JAKaL) | completed | Phase 1 | 19 | Imperial College LondonOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02837263 | PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer | completed | Phase 1 | 15 | University of Wisconsin, MadisonOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05085548 | ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies | completed | Phase 1 | 46 | ProDa BioTech, LLCINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04868773 | Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy | completed | Phase 1 | 15 | University of California, IrvineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT00885066 | Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 1 | 30 | Centre Antoine LacassagneOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT01787500 | Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | completed | Phase 1 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05304936 | HCW9218 for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 21 | ImmunityBio, Inc.INDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07529613 | Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma(T-DXd_HER2Low) | completed | Phase 1 / Phase 2 | 30 | National Cancer Center Hospital EastOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT03403049 | Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer | completed | Phase 1 | 14 | Montefiore Medical CenterOTHER | 2 | Apr 13, 2026 | clinicaltrials |
| NCT05450484 | Quantitative Fluorescence Endoscopy Using Durvalumab-680LT in Esophageal Cancer(OPTIC) | completed | Phase 1 | 21 | University Medical Center GroningenOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05107219 | GCC Agonist Signal in the Small Intestine | completed | Phase 1 | 43 | University of Wisconsin, MadisonOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04132505 | Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer | completed | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT02077881 | Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 157 | NewLink Genetics CorporationINDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03798626 | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | completed | Phase 1 | 167 | Novartis PharmaceuticalsINDUSTRY | 15 | Apr 1, 2026 | clinicaltrials |
| NCT05586516 | A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 16 | iOncturaINDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT05039177 | A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies(HERKULES-3) | completed | Phase 1 / Phase 2 | 101 | Erasca, Inc.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05411133 | Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients | completed | Phase 1 | 33 | Arbele Pty LtdINDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT06354387 | Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1 | completed | Phase 1 | 5 | China Medical University HospitalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02642809 | Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers | completed | Phase 1 | 16 | Washington University School of MedicineOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT02386397 | Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer(BREGO) | completed | Phase 1 / Phase 2 | 66 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT03223779 | Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer | completed | Phase 1 / Phase 2 | 52 | Massachusetts General HospitalOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT02213913 | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 55 | University of ChicagoOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT04332653 | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 215 | NeoImmuneTechINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03828799 | Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer(FOLFIRINOX-R) | completed | Phase 1 / Phase 2 | 13 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04526106 | REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 490 | Elevar TherapeuticsINDUSTRY | 13 | Feb 27, 2026 | clinicaltrials |
| NCT04761185 | Raltitrexed in HIPEC | completed | Phase 1 | 30 | Fudan UniversityOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT02705196 | LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | completed | Phase 1 / Phase 2 | 51 | Lokon Pharma ABINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT04426669 | A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | completed | Phase 1 / Phase 2 | 23 | Intima Bioscience, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT02021422 | A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy | completed | Phase 1 | 13 | Baylor Research InstituteOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT02073994 | Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation | completed | Phase 1 | 174 | Institut de Recherches Internationales ServierOTHER | 2 | Feb 17, 2026 | clinicaltrials |
| NCT04418401 | Study on the Safety and Efficacy of Donafinib Combined With Anti-PD-1 Antibody as Adjuvant Therapy for HCC Patients(CISLD-8) | completed | Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT03785873 | Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer | completed | Phase 1 / Phase 2 | 34 | University of Michigan Rogel Cancer CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03712943 | Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer | completed | Phase 1 | 52 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT06378047 | Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer | completed | Phase 1 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT01625351 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | completed | Phase 1 | 23 | St. Jude Children's Research HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03879694 | Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors | completed | Phase 1 | 19 | Roswell Park Cancer InstituteOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04513223 | A Phase 1 Study of SHR-A1811 in Patients With Selected HER2 Expressing Tumors | completed | Phase 1 | 101 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT03211416 | Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer | completed | Phase 1 / Phase 2 | 37 | Roswell Park Cancer InstituteOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03008278 | Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06310590 | Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma | completed | Phase 1 | 40 | Chengdu New Radiomedicine Technology Co. LTD.INDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT04752215 | A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface | completed | Phase 1 | 67 | Boehringer IngelheimINDUSTRY | 2 | Feb 2, 2026 | clinicaltrials |
| NCT04362839 | Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer | completed | Phase 1 | 39 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
Data updated 22 days agoSource updated May 22, 2026source: clinicaltrials